Advanced searches left 3/3

Metastatic Malignant Melanoma - U.S. Department of Veterans Affairs

Summarized by Plex Scholar
Last Updated: 02 November 2021

* If you want to update the article please login/register

Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma.

For patients with cerebral metastases, the diagnosis is even extra dire. Systemic immunotherapy and targeted agents are becoming the pillar of treatment for metastatic melanoma. Accumulating proof recommends that along with efficient locoregional control, radiation therapy might induce immune activation and development of T lymphocytes identifying melanocyte-specific antigens including turned on cytotoxic T lymphocytes that can possibly kill melanoma cells. Here, we evaluate the possible assurance of ablative radiation treatment in the era of contemporary immunotherapy by providing an individual with metastatic melanoma that remained condition free for over 3 years after a preliminary medical diagnosis of sophisticated metastatic melanoma with brain, subcutaneous tissue, mesenteric, pelvic, and retroperitoneal involvement. The client stopped working initial stereotactic radiosurgery, yet replied to whole-brain RT in combination with interleukin-2 immunotherapy. Thus, combination RT with immunotherapy may be collaborating by promoting the release and processing of melanoma antigens that can be offered by dendritic cells.

Source link: https://doi.org/10.1097/COC.0b013e3182940dc3

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions